An early phase I study aimed to determine the grade of inhibition of PI3K/mTOR signaling in a pre-surgery setting with Buparlisib along with potential biomarker assessment for a pathologic complete response in breast cancer patients. This evidence concerns the gene PIK3CD and breast carcinoma.